XERS - EC OK's Xeris Pharma's Ogluo for severe hypoglycaemia

Xeris Pharmaceuticals (XERS) jumps 13% premarket in reaction to the announcement that the European Commission ((EC)) has approved Ogluo (glucagon) injection for the treatment of severe hypoglycaemia in pediatric and adult patients with diabetes ages 2 years and above.The marketing authorization is valid in all 27 countries of the European Union, plus Iceland, Norway, and Liechtenstein.Xeris is yet to complete a further administrative step to obtain a license in Great Britain.Gvoke PFS and Gvoke HypoPen (glucagon injection) were approved in U.S. in September 2019.Ogluo received a positive opinion from the EMA's advisory committee in December 2020.

For further details see:

EC OK's Xeris Pharma's Ogluo for severe hypoglycaemia